Videos / New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3
In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).
Menopause and MHT: Maximising Benefits & Minimising Risks
Multiple Sclerosis vs Antibody Disease – What GPs Need to Know
Using SGLT2 to Reduce Cardiovascular Death in T2D – Important Updates for GPs
Peripheral Arterial Disease
expert
Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland